

Financial Results  
for the First Half of the Fiscal Year  
Ending March 31, 2011

October 28, 2010

TERUMO Corporation

# Financial Results

(Unit: Billions of yen)

	1H Mar. 2010	1H Mar. 2011	YoY (%)
Net Sales	158.1	163.9	4%
Gross Profit	83.3 (52.7%)	85.6 (52.2%)	3%
SG&A Expenses	50.7 (32.1%)	52.9 (32.2%)	4%
Operating Income	32.6 (20.6%)	32.7 (20.0%)	0%
Ordinary Income	32.2 (20.4%)	28.2 (17.2%)	-13%
Net Income	20.8 (13.1%)	18.4 (11.2%)	-12%
Average foreign exchange rates	US\$ 96yen EUR 133yen	89yen 114yen	} Impact on Net Sales -4%


# Net Sales (by Region)

(Unit: Billions of yen)

Consolidated: +4% (+8%)

■ Mar. 2010  
■ Mar. 2011  
 1H 1H

( ): Constant currency



Ratio of Overseas Net Sales 45% → 45%

# Factors of the Overseas Favorable Performance

## Interventional systems drive

■ Europe: 22% growth


-Sales of Drug Eluting Stent  
“Nobori” doubled

■ U.S.: 17% growth

-The Smooth spread of TRI  
procedure contributes the sales  
increase of other related  
products

## High growth in emerging country

\*% based on constant currency




# Net Sales (by Business Segment)


(Unit: Billions of yen)

■ Mar. 2010  
■ Mar. 2011  
 1H 1H

( ): Constant currency



# Gross Profit Rate Variance Analysis



Mar. 2010  
1H

Average Exchange Rates	1H Mar. 2010	1H Mar. 2011
US\$:	96yen	89yen
EUR :	133yen	114yen

Mar. 2011  
1H

# SG&A Expenses

(Unit: Billions of yen)

	1H Mar. 2010	1H Mar. 2011	YoY	YoY%
Salaries & wages	19.1	19.5	+0.4	+2%
Sales Promotion	5.2	5.1	-0.1	-2%
Logistical costs	4.4	4.7	+0.3	+7%
Depreciation & Amortization	2.6	2.3	-0.3	-13%
Others	11.2	11.5	+0.3	+3%
General Administrative Total	<b>42.5</b> (26.9%)	<b>43.1</b> (26.2%)	<b>+0.6</b>	<b>+1%</b>
R&D Expenses	<b>8.2</b> (5.2%)	<b>9.8</b> (6.0%)	<b>+1.6</b>	<b>+20%</b>
<b>SG&amp;A TOTAL</b>	<b>50.7</b> (32.1%)	<b>52.9</b> (32.2%)	<b>+2.2</b>	<b>+4%</b>

# Full Year Forecast for the FYE Mar. 2011


Revised the foreign exchange rate forecasts of 2nd half and the full year

(Unit: Billions of yen)

	Mar. 2011 Original Forecast	Mar. 2011 Revised Forecast	Change
Net Sales	333.0	326.0	-7.0
Operating Income	65.2 (19.6%)	63.3 (19.4%)	-1.9
Ordinary Income	65.0 (19.5%)	57.2 (17.5%)	-7.8
Net Income	41.5 (12.5%)	36.3 (11.1%)	-5.2
Assumed foreign exchange rates	2H    Full Year US\$ 90yen    90 yen EUR 120yen    120 yen	2H    Full Year US\$ 80yen    85yen EUR 113yen    113 yen	



# For the Future Growth



1) Endoscopic  
Guidewire


Hydrophobic  
Coating

Swellable  
Coating



2) Cerebrovascular  
Embolization Coil

Hydrophilic  
Coating



- Guidewires for  
Angiography/Treatment
- Sheaths for TRI Procedures

# Strategically Develop Innovative Products

- \*Thoroughly benchmark the product with highest shares
- \*Survey the market needs beyond the framework of alliance



Satisfies the 2 contradictory requirements of “thinness” and “rigidity”.  
Enables almost all treatments with one guidewire.

- Advantages
- Shorter procedure time
  - No trouble in selecting a device per individual case
  - Contributing to the healthcare economy

## Change the Market by Forming a Partnership

- Conditions before development

- The most important device in endoscopic treatment
- Overseas manufacturers dominated the guidewire market

- Purpose of development

**Best in-the-world technology  
in guidewires**

**Overwhelming sales power  
in an endoscopic field**



Change the market by producing ideal guidewires  
desired by doctors

## Our Innovative Technology Evaluated by the Market

---

- October 2009: Began selling the products designed for the market outside Japan
- April 2010: Began selling the products designed for the market within Japan

Evoked a great response after the release

10% market share in the U.S., 20% market share in Japan





Target to “Gain 30% global share within the next 3 years”  
is within our reach

Become No.1 in the global market by continuing to  
improve the products through further collaboration

## 2) Cerebrovascular Embolization Coil


# To Expand the Neuro Market with Our Unique Technology

- Cerebrovascular embolization coil




## Trends in Cerebrovascular Treatments

Surgical clipping  
by a craniotomy



Still prevalent within Japan

Coiling treatment



Widespread  
within Europe & U.S.

In the future, there will be a shift towards  
less invasive coiling treatment in Japan

# Superiority of HydroCoils

- Characteristics of HydroCoil

- Expands by reacting to the blood, and fills up inside of an aneurysm
- One and only technology in the world



- The result of HELPS\*

\*2010: 7 countries from Europe and U.S., Randomized clinical trial of HydroCoil against Bare Coil


Rating Category	HydroCoil	Bare coils	
Aneurysm filling rate	68.3%	24.9%	HydroCoils have a high filling rate
Aneurysm recurrence rate	HydroCoils are 8.6% lower in comparison with bare coils		There is a statistically significant difference
Retreatment rate	2.9%	3.6%	HydroCoils are superior

## Domestic Growth Strategies for Neuro Business

1. Continuous launch of new products
2. Strengthen evidence
3. Improve sales organization

Triple both sales and share

(Unit: Billions of yen)



FY12 To become No.1 in the neuro business within Japan



---

# Reference

# Income for the 1st Half of the FYE Mar. 2011: To the Forecast for the 1st Half

(Unit: Billions of yen)

	<u>1H</u> <u>Original Forecast</u>	<u>1H</u> <u>Results</u>	<u>Changes</u>	<u>Impact of</u> <u>Foreign Exchange</u>
Net Sales	164.0	163.9	-0.1	- 1.3
Operating Income	32.6 (19.9%)	32.7 (20.0%)	+0.1	- 0.5
Ordinary Income	32.5 (19.8%)	28.2 (17.2%)	-4.3	
Net Income	20.8 (12.7%)	18.4 (11.2%)	-2.4	

Foreign exchange  
rates

Assumed

US\$	90yen	89yen
EUR	120yen	114yen

# Income for the 1st Half of the FYE Mar. 2011: To the Forecast for the Full Year


(Unit: Billions of yen)

	<u>Full Year</u> <u>Revised Forecast</u>	<u>1H</u> <u>Results</u>	<u>Progress</u> <u>Rates</u>	<u>Impact of</u> <u>Foreign Exchange</u>
Net Sales	326.0	163.9	50%	-1.3 (Lower progress rate by 0.4%)
Operating Income	63.3 (19.4%)	32.7 (20.0%)	52%	-0.5 (Lower progress rate by 0.8%)
Ordinary Income	57.2 (17.5%)	28.2 (17.2%)	49%	
Net Income	36.3 (11.1%)	18.4 (11.2%)	51%	


---

Foreign exchange rates	<u>Forecast</u>	
US\$	85yen	89yen
EUR	113yen	114yen

# Gross Profit, SG&A, Operating Income Rates



# Changes of Quarterly Average Exchange Rates



# ***IR Contact***

---

## **TERUMO Corporation**

**Corporate Communication (IR) Dept.**

**E-mail: [kouhou\\_terumo01@terumo.co.jp](mailto:kouhou_terumo01@terumo.co.jp)**

Among the information that Terumo discloses, forecasts of financial performance on future projections contain potential risks and uncertainty since these are forecasts on projections made by Terumo based on limited information available at the moment of disclosure. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

The market share information in this presentation is partly derived from our own independent research.